307 related articles for article (PubMed ID: 31545405)
1. Sorafenib inhibits vascular endothelial cell proliferation stimulated by anaplastic thyroid cancer cells regardless of BRAF mutation status.
Ishihara S; Onoda N; Noda S; Asano Y; Tauchi Y; Morisaki T; Kashiwagi S; Takashima T; Ohira M
Int J Oncol; 2019 Nov; 55(5):1069-1076. PubMed ID: 31545405
[TBL] [Abstract][Full Text] [Related]
2. CLM29 and CLM24, pyrazolopyrimidine derivatives, have antitumoral activity in vitro in anaplastic thyroid cancer, with or without BRAF mutation.
Fallahi P; Ferrari SM; La Motta C; Materazzi G; Bocci G; Da Settimo F; Miccoli P; Antonelli A
Endocrine; 2016 Jul; 53(1):136-44. PubMed ID: 26286966
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status.
Broecker-Preuss M; Müller S; Britten M; Worm K; Schmid KW; Mann K; Fuhrer D
BMC Cancer; 2015 Mar; 15():184. PubMed ID: 25879531
[TBL] [Abstract][Full Text] [Related]
4. Growth arrest by activated BRAF and MEK inhibition in human anaplastic thyroid cancer cells.
Kurata K; Onoda N; Noda S; Kashiwagi S; Asano Y; Hirakawa K; Ohira M
Int J Oncol; 2016 Dec; 49(6):2303-2308. PubMed ID: 27748799
[TBL] [Abstract][Full Text] [Related]
5. Combination
Gunda V; Ghosh C; Hu J; Zhang L; Zhang YQ; Shen M; Kebebew E
Thyroid; 2023 Oct; 33(10):1201-1214. PubMed ID: 37675898
[No Abstract] [Full Text] [Related]
6. Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis.
Sadowski SM; Boufraqech M; Zhang L; Mehta A; Kapur P; Zhang Y; Li Z; Shen M; Kebebew E
Oncotarget; 2015 Jul; 6(20):18038-49. PubMed ID: 25945839
[TBL] [Abstract][Full Text] [Related]
7. Case report: Complete response of an anaplastic thyroid carcinoma patient with
Gui L; Zhu Y; Li X; He X; Ma T; Cai Y; Liu S
Front Immunol; 2023; 14():1178682. PubMed ID: 37122752
[TBL] [Abstract][Full Text] [Related]
8. Expression of angiogenic switch, cachexia and inflammation factors at the crossroad in undifferentiated thyroid carcinoma with BRAF(V600E).
Husain A; Hu N; Sadow PM; Nucera C
Cancer Lett; 2016 Oct; 380(2):577-585. PubMed ID: 26189429
[TBL] [Abstract][Full Text] [Related]
9. Distribution and Activity of Lenvatinib in Brain Tumor Models of Human Anaplastic Thyroid Cancer Cells in Severe Combined Immune Deficient Mice.
Wang R; Yamada T; Arai S; Fukuda K; Taniguchi H; Tanimoto A; Nishiyama A; Takeuchi S; Yamashita K; Ohtsubo K; Matsui J; Onoda N; Hirata E; Taira S; Yano S
Mol Cancer Ther; 2019 May; 18(5):947-956. PubMed ID: 30926637
[TBL] [Abstract][Full Text] [Related]
10. S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAFV600E/Mt to Vemurafenib.
Jiao X; Zhang H; Xu X; Yu Y; Zhang H; Zhang J; Ning L; Hao F; Liu X; Niu M; Chen CT; Chen D; Zhang K
Cell Physiol Biochem; 2018; 49(3):1143-1162. PubMed ID: 30196299
[TBL] [Abstract][Full Text] [Related]
11. Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations.
Preto A; Gonçalves J; Rebocho AP; Figueiredo J; Meireles AM; Rocha AS; Vasconcelos HM; Seca H; Seruca R; Soares P; Sobrinho-Simões M
BMC Cancer; 2009 Oct; 9():387. PubMed ID: 19878585
[TBL] [Abstract][Full Text] [Related]
12. Signal transducer and activator of transcription 3 inhibition alleviates resistance to BRAF inhibition in anaplastic thyroid cancer.
Wang Y; Hu Z; Ma W; Niu Y; Su J; Zhang L; Zhao P
Invest New Drugs; 2021 Jun; 39(3):764-774. PubMed ID: 33245464
[TBL] [Abstract][Full Text] [Related]
13. Disruption of mutated BRAF signaling modulates thyroid cancer phenotype.
Hanly EK; Rajoria S; Darzynkiewicz Z; Zhao H; Suriano R; Tuli N; George AL; Bednarczyk R; Shin EJ; Geliebter J; Tiwari RK
BMC Res Notes; 2014 Mar; 7():187. PubMed ID: 24673746
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib and Quinacrine Target Anti-Apoptotic Protein MCL1: A Poor Prognostic Marker in Anaplastic Thyroid Cancer (ATC).
Abdulghani J; Gokare P; Gallant JN; Dicker D; Whitcomb T; Cooper T; Liao J; Derr J; Liu J; Goldenberg D; Finnberg NK; El-Deiry WS
Clin Cancer Res; 2016 Dec; 22(24):6192-6203. PubMed ID: 27307592
[TBL] [Abstract][Full Text] [Related]
15. Synergistic anticancer activity of sorafenib, paclitaxel, and radiation therapy on anaplastic thyroid cancer in vitro and in vivo.
Kim SY; Kim SM; Chang H; Chang HS; Park CS; Lee YS
Head Neck; 2020 Dec; 42(12):3678-3684. PubMed ID: 32896015
[TBL] [Abstract][Full Text] [Related]
16. BRAF Inhibition in BRAFV600E-Positive Anaplastic Thyroid Carcinoma.
Lim AM; Taylor GR; Fellowes A; Cameron L; Lee B; Hicks RJ; McArthur GA; Angel C; Solomon B; Rischin D
J Natl Compr Canc Netw; 2016 Mar; 14(3):249-54. PubMed ID: 26957611
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of HRAS and CDK4/6 inhibitors in anaplastic thyroid cancer cell lines.
Lopes-Ventura S; Pojo M; Matias AT; Moura MM; Marques IJ; Leite V; Cavaco BM
J Endocrinol Invest; 2019 May; 42(5):527-540. PubMed ID: 30191474
[TBL] [Abstract][Full Text] [Related]
18. Inhibiting ERK dimerization ameliorates BRAF-driven anaplastic thyroid cancer.
Zaballos MA; Acuña-Ruiz A; Morante M; Riesco-Eizaguirre G; Crespo P; Santisteban P
Cell Mol Life Sci; 2022 Sep; 79(9):504. PubMed ID: 36056964
[TBL] [Abstract][Full Text] [Related]
19. Synergistic Anticancer Activity of
Yun HJ; Kim HJ; Kim J; Kim SY; Chang HS; Park CS; Chang HJ; Park KC
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33430361
[TBL] [Abstract][Full Text] [Related]
20. Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer.
Latteyer S; Tiedje V; König K; Ting S; Heukamp LC; Meder L; Schmid KW; Führer D; Moeller LC
Endocrine; 2016 Dec; 54(3):733-741. PubMed ID: 27696251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]